Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for ARQT

Stock Name	Arcutis Biotherapeutics Inc
Ticker	ARQT(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US03969K1088

Show aggregate ARQT holdings

News associated with ARQT

Zurcher Kantonalbank Zurich Cantonalbank Raises Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 3.2% in the first quarter, HoldingsChannel reports. The institutional investor owned 29,697 shares of the company’s stock after purchasing an additional 917 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Arcutis Biotherapeutics were worth $464,000 at the […] - 2025-08-08 04:56:49
Arcutis Biotherapeutics (NASDAQ:ARQT) Coverage Initiated at The Goldman Sachs Group: The Goldman Sachs Group began coverage on shares of Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) in a research report released on Friday, MarketBeat.com reports. The brokerage issued a neutral rating and a $18.00 price target on the stock. A number of other brokerages have also commented on ARQT. Needham & Company LLC reiterated a “buy” […] - 2025-07-28 02:05:01
Patrick Burnett Sells 23,000 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) insider Patrick Burnett sold 23,000 shares of the company’s stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $15.05, for a total value of $346,150.00. Following the sale, the insider owned 115,468 shares of the company’s stock, valued at […] - 2025-07-16 05:29:11
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Recommendation of “Moderate Buy” from Analysts: Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) have received an average recommendation of “Moderate Buy” from the six brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price […] - 2025-07-10 05:48:58
SG Americas Securities LLC Has $509,000 Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): SG Americas Securities LLC lowered its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 32.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 32,566 shares of the company’s stock after selling 15,521 shares during the period. SG Americas Securities […] - 2025-06-23 04:29:10
Wealth Enhancement Advisory Services LLC Purchases Shares of 20,912 Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 20,912 shares of the company’s stock, valued at approximately $291,000. Other hedge funds and other institutional investors have also bought and sold shares of the […] - 2025-06-16 04:08:49
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 1.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 280,100 shares of the company’s stock […] - 2025-06-05 05:16:57
Analysts Anticipate 25% Gains Ahead For The Holdings of FHLC: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-29 08:03:59
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by Deutsche Bank AG: Deutsche Bank AG lessened its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 51.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 387,536 shares of the company’s stock after selling 412,491 shares during the quarter. Deutsche Bank AG’s holdings […] - 2025-05-19 05:07:00
Northern Trust Corp Purchases 54,541 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Northern Trust Corp increased its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 5.8% during the fourth quarter, HoldingsChannel reports. The fund owned 991,056 shares of the company’s stock after buying an additional 54,541 shares during the quarter. Northern Trust Corp’s holdings in Arcutis Biotherapeutics were worth $13,805,000 at the end […] - 2025-05-16 04:22:56
Schonfeld Strategic Advisors LLC Sells 7,349 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Schonfeld Strategic Advisors LLC lessened its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 24.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,000 shares of the company’s stock after selling 7,349 shares during the quarter. Schonfeld Strategic Advisors […] - 2025-05-13 06:15:01
Price T Rowe Associates Inc. MD Reduces Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Price T Rowe Associates Inc. MD decreased its position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 29.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 42,349 shares of the company’s stock after selling 17,799 shares during the […] - 2025-05-13 04:32:49
Voya Investment Management LLC Sells 2,472 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Voya Investment Management LLC trimmed its position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 7.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 32,136 shares of the company’s stock after selling 2,472 shares during the period. Voya Investment […] - 2025-05-11 05:44:48
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Position Boosted by Tower Research Capital LLC TRC: Tower Research Capital LLC TRC grew its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 62.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,231 shares of the company’s stock after buying an additional 5,488 shares during the quarter. […] - 2025-05-06 05:09:04
Wells Fargo & Company MN Has $731,000 Stock Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Wells Fargo & Company MN increased its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 46.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 52,455 shares of the company’s stock after purchasing an additional 16,682 shares during the quarter. Wells Fargo & Company MN’s holdings in Arcutis Biotherapeutics were […] - 2025-05-02 04:18:56
Geode Capital Management LLC Increases Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Geode Capital Management LLC boosted its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 0.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 2,472,730 shares of the company’s stock after buying an additional 2,592 shares during the quarter. Geode Capital Management LLC’s holdings in Arcutis Biotherapeutics were worth $34,453,000 as of […] - 2025-04-17 05:18:49
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by Wellington Management Group LLP: Wellington Management Group LLP lowered its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 7.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 49,267 shares of the company’s stock after selling 3,882 shares during the quarter. Wellington Management Group LLP’s holdings in Arcutis Biotherapeutics […] - 2025-04-15 04:46:50
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by CIBC Private Wealth Group LLC: CIBC Private Wealth Group LLC reduced its position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 18.6% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 7,782 shares of the company’s stock after selling 1,776 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Arcutis […] - 2025-04-08 06:03:20
Teacher Retirement System of Texas Boosts Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Teacher Retirement System of Texas grew its position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 19.5% during the 4th quarter, HoldingsChannel reports. The fund owned 31,216 shares of the company’s stock after purchasing an additional 5,087 shares during the period. Teacher Retirement System of Texas’ holdings in Arcutis Biotherapeutics were worth $435,000 at […] - 2025-04-01 04:40:45
Intech Investment Management LLC Buys 5,168 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Intech Investment Management LLC boosted its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 13.9% during the fourth quarter, Holdings Channel.com reports. The fund owned 42,258 shares of the company’s stock after acquiring an additional 5,168 shares during the period. Intech Investment Management LLC’s holdings in Arcutis Biotherapeutics were worth $589,000 […] - 2025-03-25 06:29:08
AlphaQuest LLC Decreases Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): AlphaQuest LLC lessened its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 83.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 7,142 shares of the company’s stock after selling 35,696 shares during the quarter. AlphaQuest LLC’s holdings in Arcutis Biotherapeutics were worth $99,000 as of its most recent filing […] - 2025-03-19 06:10:46
Bank of New York Mellon Corp Cuts Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT): Bank of New York Mellon Corp decreased its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 1.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 305,007 shares of the company’s stock after selling 6,052 shares during the period. Bank […] - 2025-03-19 05:08:45
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says: Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) had its price target lifted by Jefferies Financial Group from $16.00 to $19.00 in a research report report published on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock. Other research analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating […] - 2025-03-12 04:56:51
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Expected to Rise, Mizuho Analyst Says: Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) had its target price lifted by stock analysts at Mizuho from $20.00 to $21.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s target price suggests a potential upside of 64.06% from the stock’s previous close. A number of […] - 2025-02-28 04:52:44

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc ARQT holdings

Date	Number of ARQT Shares Held	Base Market Value of ARQT Shares	Local Market Value of ARQT Shares	Change in ARQT Shares Held	Change in ARQT Base Value	Current Price per ARQT Share Held	Previous Price per ARQT Share Held
2025-09-26 (Friday)	55,701	USD 978,667	USD 978,667
2025-09-25 (Thursday)	55,701	USD 931,878	USD 931,878	0	USD -31,749	USD 16.73	USD 17.3
2025-09-24 (Wednesday)	55,701	USD 963,627	USD 963,627
2025-09-17 (Wednesday)	55,339	USD 948,510	USD 948,510	0	USD 9,407	USD 17.14	USD 16.97
2025-09-16 (Tuesday)	55,339	USD 939,103	USD 939,103
2025-09-12 (Friday)	54,977	USD 950,552	USD 950,552
2025-09-11 (Thursday)	54,977	USD 972,543	USD 972,543

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ARQT by Blackrock for IE00B3VWM098

Show aggregate share trades of ARQT

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-08-21 SELL -181 15.790* 13.35 Profit of 2,417 on sale
2025-07-31 BUY 540 14.580* 13.33
2025-06-30 SELL -362 14.020* 13.18 Profit of 4,771 on sale
2025-06-25 SELL -181 14.470* 13.16 Profit of 2,382 on sale
2025-06-20 SELL -362 13.820* 13.14 Profit of 4,755 on sale
2025-05-23 BUY 181 13.980* 13.05
2025-05-19 SELL -181 14.640* 13.01 Profit of 2,355 on sale
2025-05-15 SELL -543 13.630* 13.00 Profit of 7,058 on sale
2025-05-12 SELL -181 14.390* 12.97 Profit of 2,348 on sale
2025-05-09 SELL -181 13.530* 12.97 Profit of 2,347 on sale
2025-04-30 SELL -181 14.910* 12.86 Profit of 2,328 on sale
2025-04-24 SELL -362 14.720* 12.79 Profit of 4,629 on sale
2025-04-17 SELL -181 13.010* 12.75 Profit of 2,307 on sale
2025-04-15 SELL -543 13.190* 12.74 Profit of 6,918 on sale
2025-04-14 SELL -543 12.940* 12.74 Profit of 6,917 on sale
2025-04-09 SELL -724 14.570* 12.71 Profit of 9,203 on sale
2025-04-07 SELL -1,267 14.300* 12.69 Profit of 16,073 on sale
2025-04-04 SELL -1,810 14.730* 12.66 Profit of 22,917 on sale
2025-03-31 BUY 181 15.640* 12.55
2025-03-19 SELL -362 16.600* 12.11 Profit of 4,383 on sale
2025-03-14 SELL -1,086 14.620* 11.96 Profit of 12,987 on sale
2025-03-13 SELL -364 14.810* 11.92 Profit of 4,338 on sale
2025-03-12 SELL -6,188 15.160* 11.87 Profit of 73,455 on sale
2025-03-07 SELL -364 14.720* 11.73 Profit of 4,271 on sale
2025-03-06 SELL -546 14.500* 11.69 Profit of 6,384 on sale
2025-03-03 SELL -182 12.830* 11.60 Profit of 2,111 on sale
2025-02-28 SELL -1,092 13.690* 11.56 Profit of 12,626 on sale
2025-02-26 SELL -182 13.220* 11.51 Profit of 2,095 on sale
2025-02-25 SELL -546 12.200* 11.50 Profit of 6,280 on sale
2025-02-18 BUY 910 12.510* 11.37
2025-02-13 BUY 182 12.310* 11.30
2025-02-12 BUY 182 13.210* 11.26
2025-02-11 BUY 546 11.400* 11.26
2025-02-06 BUY 1,638 12.420* 11.21
2025-01-27 BUY 182 14.250* 10.73
2024-12-30 BUY 910 14.200* 10.32
2024-12-06 BUY 724 12.400* 10.08
2024-12-05 BUY 181 12.310* 10.01
2024-12-04 BUY 905 12.610* 9.91
2024-11-29 BUY 905 13.040* 9.59
2024-11-27 BUY 724 11.710* 9.41
2024-11-26 BUY 181 11.510* 9.32
2024-11-25 SELL -12,403 10.770* 9.25 Profit of 114,675 on sale
2024-11-21 BUY 1,095 10.240* 9.15
2024-11-20 BUY 657 10.180* 9.09
2024-11-18 BUY 2,628 9.430* 9.01
2024-11-12 BUY 1,744 10.250* 8.92
2024-11-08 BUY 1,090 10.820* 8.79
2024-11-07 BUY 3,270 10.400* 8.66
2024-11-06 BUY 436 9.660* 8.58
2024-10-31 BUY 218 8.310* 8.49
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-08-21	SELL	-181	15.790*	13.35 Profit of 2,417 on sale
2025-07-31	BUY	540	14.580*	13.33
2025-06-30	SELL	-362	14.020*	13.18 Profit of 4,771 on sale
2025-06-25	SELL	-181	14.470*	13.16 Profit of 2,382 on sale
2025-06-20	SELL	-362	13.820*	13.14 Profit of 4,755 on sale
2025-05-23	BUY	181	13.980*	13.05
2025-05-19	SELL	-181	14.640*	13.01 Profit of 2,355 on sale
2025-05-15	SELL	-543	13.630*	13.00 Profit of 7,058 on sale
2025-05-12	SELL	-181	14.390*	12.97 Profit of 2,348 on sale
2025-05-09	SELL	-181	13.530*	12.97 Profit of 2,347 on sale
2025-04-30	SELL	-181	14.910*	12.86 Profit of 2,328 on sale
2025-04-24	SELL	-362	14.720*	12.79 Profit of 4,629 on sale
2025-04-17	SELL	-181	13.010*	12.75 Profit of 2,307 on sale
2025-04-15	SELL	-543	13.190*	12.74 Profit of 6,918 on sale
2025-04-14	SELL	-543	12.940*	12.74 Profit of 6,917 on sale
2025-04-09	SELL	-724	14.570*	12.71 Profit of 9,203 on sale
2025-04-07	SELL	-1,267	14.300*	12.69 Profit of 16,073 on sale
2025-04-04	SELL	-1,810	14.730*	12.66 Profit of 22,917 on sale
2025-03-31	BUY	181	15.640*	12.55
2025-03-19	SELL	-362	16.600*	12.11 Profit of 4,383 on sale
2025-03-14	SELL	-1,086	14.620*	11.96 Profit of 12,987 on sale
2025-03-13	SELL	-364	14.810*	11.92 Profit of 4,338 on sale
2025-03-12	SELL	-6,188	15.160*	11.87 Profit of 73,455 on sale
2025-03-07	SELL	-364	14.720*	11.73 Profit of 4,271 on sale
2025-03-06	SELL	-546	14.500*	11.69 Profit of 6,384 on sale
2025-03-03	SELL	-182	12.830*	11.60 Profit of 2,111 on sale
2025-02-28	SELL	-1,092	13.690*	11.56 Profit of 12,626 on sale
2025-02-26	SELL	-182	13.220*	11.51 Profit of 2,095 on sale
2025-02-25	SELL	-546	12.200*	11.50 Profit of 6,280 on sale
2025-02-18	BUY	910	12.510*	11.37
2025-02-13	BUY	182	12.310*	11.30
2025-02-12	BUY	182	13.210*	11.26
2025-02-11	BUY	546	11.400*	11.26
2025-02-06	BUY	1,638	12.420*	11.21
2025-01-27	BUY	182	14.250*	10.73
2024-12-30	BUY	910	14.200*	10.32
2024-12-06	BUY	724	12.400*	10.08
2024-12-05	BUY	181	12.310*	10.01
2024-12-04	BUY	905	12.610*	9.91
2024-11-29	BUY	905	13.040*	9.59
2024-11-27	BUY	724	11.710*	9.41
2024-11-26	BUY	181	11.510*	9.32
2024-11-25	SELL	-12,403	10.770*	9.25 Profit of 114,675 on sale
2024-11-21	BUY	1,095	10.240*	9.15
2024-11-20	BUY	657	10.180*	9.09
2024-11-18	BUY	2,628	9.430*	9.01
2024-11-12	BUY	1,744	10.250*	8.92
2024-11-08	BUY	1,090	10.820*	8.79
2024-11-07	BUY	3,270	10.400*	8.66
2024-11-06	BUY	436	9.660*	8.58
2024-10-31	BUY	218	8.310*	8.49

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ARQT

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	341,726	35,090	772,423	44.2%
2025-09-18	165,661	1,522	363,887	45.5%
2025-09-17	284,725	0	630,736	45.1%
2025-09-16	179,844	22	395,466	45.5%
2025-09-15	175,552	0	491,917	35.7%
2025-09-12	307,525	0	657,235	46.8%
2025-09-11	258,316	280	539,943	47.8%
2025-09-10	437,027	1,316	950,925	46.0%
2025-09-09	532,770	0	1,150,718	46.3%
2025-09-08	452,889	5,712	986,459	45.9%
2025-09-05	361,617	50	1,130,359	32.0%
2025-09-04	366,561	100	1,012,477	36.2%
2025-09-03	292,438	175	835,684	35.0%
2025-09-02	228,380	100	443,104	51.5%
2025-08-29	226,806	1,350	420,494	53.9%
2025-08-28	256,315	377	611,736	41.9%
2025-08-27	144,101	0	315,281	45.7%
2025-08-26	209,333	0	530,210	39.5%
2025-08-25	180,217	50	442,972	40.7%
2025-08-22	147,996	0	373,958	39.6%
2025-08-21	89,117	0	274,940	32.4%
2025-08-20	175,749	54	518,920	33.9%
2025-08-19	86,602	0	356,660	24.3%
2025-08-18	152,543	34,957	607,121	25.1%
2025-08-15	136,335	0	738,567	18.5%
2025-08-14	196,629	0	845,242	23.3%
2025-08-13	166,144	452	1,181,490	14.1%
2025-08-12	146,797	0	602,664	24.4%
2025-08-11	270,539	384	620,441	43.6%
2025-08-08	386,298	25,035	1,202,815	32.1%
2025-08-07	1,109,375	22,631	1,675,042	66.2%
2025-08-06	341,028	1,278	574,755	59.3%
2025-08-05	223,064	170	693,798	32.2%
2025-08-04	217,706	41	446,616	48.7%
2025-08-01	401,671	3,150	744,554	53.9%
2025-07-31	177,568	572	398,666	44.5%
2025-07-30	265,582	600	669,791	39.7%
2025-07-29	251,383	2,815	615,844	40.8%
2025-07-28	302,393	0	690,493	43.8%
2025-07-25	450,530	0	755,422	59.6%
2025-07-24	186,949	515	400,240	46.7%
2025-07-23	169,528	0	376,358	45.0%
2025-07-22	284,845	0	536,876	53.1%
2025-07-21	278,122	570	433,724	64.1%
2025-07-18	282,650	0	669,379	42.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE